Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-Year median followup from the Scandinavian Prostate Cancer Group Study Number 6

Journal of Urology

Volumn 172, Issue 5 I, 2004, Pages 1871-1876

  Iversen, Peter ^a   Johansson, Jan Erik ^b   Lodding, Pär ^b   Lukkarinen, Olavi ^b   Lundmo, Per ^b   Klarskov, Peter ^b   Tammela, Teuvo L J ^b   Tasdemir, Ilker ^b   Morris, Tom ^b   Carroll, Kevin ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE

Author keywords

Bicalutamide; Bioethics; Prostate; Prostatic neoplasms; Survival

Indexed keywords

BICALUTAMIDE; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FLU LIKE SYNDROME; FOLLOW UP; GYNECOMASTIA; HEART FAILURE; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MASTALGIA; NAUSEA; PAIN; PELVIS PAIN SYNDROME; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE RETENTION; VERTIGO;

EID: 5444257477     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000139719.99825.54     Document Type: Article

References (20)

1. Chuba, P. J., Moughan, J., Forman, J. D., Owen, J. and Hanks, G.: The 1989 patterns of care study for prostate cancer: five-year outcomes. Int J Radiat Oncol Biol Phys, 50: 325, 2001
2. Grossfeld, G. D., Stier, D. M., Flanders, S. C., Henning, J. M., Schonfeld, W., Warolin, K. et al: Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. J Urol, 160: 1398, 1998
3. Koppie, T. M., Grossfeld, G. D., Miller, D., Yu, J., Stier, D., Broering, J. M. et al: Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from the CaPSURE database. J Urol, 164: 81, 2000
4. Swanson, G. P., Riggs, M. W., Earle, J. D. and Haddock, M. G.: Long-term follow-up of radical retropubic prostatectomy for prostate cancer. Eur Urol, 42: 212, 2002
5. Zietman, A. L., Thakral, H., Wilson, L. and Schellhammer, P.: Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol, 166: 1702, 2001
6. D'Amico, A. V., Whittington, R., Malkowicz, S. B., Fondurulia, J., Chen, M. H., Kaplan, I. et al: Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol, 17: 168, 1999
7. Graefen, M., Noldus, J., Pichlmeier, U., Haese, A., Hammerer, P., Fernandez, S. et al: Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol, 36: 21, 1999
8. Zagars, G. K., Pollack, A. and von Eschenbach, A. C.: Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer, 80: 764, 1997
9. See, W. A., McLeod, D., Iversen, P. and Wirth, M.: The bicalutamide Early Prostate Cancer Program. Demography. Urol Oncol, 6: 43, 2001
10. See, W. A., Wirth, M. P., McLeod, D. G., Iversen, P., Klimberg, I., Gleason, D. et al: Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol, 168: 429, 2002
11. Iversen, P., Tammela, T. L., Vaage, S., Lukkarinen, O., Lodding, P., Bull-Njaa, T. et al: A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. Eur Urol, 42: 204, 2002
12. Gail, M. and Simon, R.: Testing for qualitative interactions between treatment effects and patient subsets. Biometrics, 41: 361, 1985
13. Klotz, L.: Expectant management with selective delayed intervention for favorable risk prostate cancer. Urol Oncol, 7: 175, 2002
14. Kirk, D. and on behalf of MRC Prostate Cancer Working Party Investigations Group: Does hormonal treatment for prostate cancer cause excess deaths: data from the MRC Immediate vs Deferred Hormone Treatment Study. BJU Int, suppl., 83: 9, abstract 71, 1999
15. Kirk, D.: Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation? Br J Urol, suppl., 86: 220, 2000
16. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol, 79: 235, 1997
17. Smith, J. A., Jr., Soloway, M. S. and Young, M. J.: Complications of advanced prostate cancer. Urology, suppl., 54: 8, 1999
18. Ullrich, P. M., Carson, M. R., Lutgendorf, S. K. and Williams, R. D.: Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence. J Urol, 169: 1449, 2003
19. Iversen, P., Tyrrell, C. J., Kaisary, A. V., Anderson, J. B., Van Poppel, H., Tammela, T. L. J. et al: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol, 184: 1579, 2000
20. Sieber, P. R., Keiller, D. L., Kahnoski, R. J., Garcia-Vargas, J. E., Gallo, J. and McFadden, S.: Bone mineral density is maintained during bicalutamide ('Casodex') treatment. Proc Am Soc Clin Oncol, 21: 196a, 2002